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Abstract
Vav1 is a signal transducer protein that functions as a guanine nucleotide exchange factor for the Rho/Rac GTPases in the
hematopoietic system where it is exclusively expressed. Recently, Vav1 was shown to be involved in several human
malignancies including neuroblastoma, lung cancer, and pancreatic ductal adenocarcinoma (PDA). Although some factors
that affect vav1 expression are known, neither the physiological nor pathological regulation of vav1 expression is
completely understood. We demonstrate herein that mutations in putative transcription factor binding sites at the vav1
promoter affect its transcription in cells of different histological origin. Among these sites is a consensus site for c-Myb, a
hematopoietic-specific transcription factor that is also found in Vav1-expressing lung cancer cell lines. Depletion of c-Myb
using siRNA led to a dramatic reduction in vav1 expression in these cells. Consistent with this, co-transfection of c-Myb
activated transcription of a vav1 promoter-luciferase reporter gene construct in lung cancer cells devoid of Vav1 expression.
Together, these results indicate that c-Myb is involved in vav1 expression in lung cancer cells. We also explored the
methylation status of the vav1 promoter. Bisulfite sequencing revealed that the vav1 promoter was completely
unmethylated in human lymphocytes, but methylated to various degrees in tissues that do not normally express vav1. The
vav1 promoter does not contain CpG islands in proximity to the transcription start site; however, we demonstrated that
methylation of a CpG dinucleotide at a consensus Sp1 binding site in the vav1 promoter interferes with protein binding in
vitro. Our data identify two regulatory mechanisms for vav1 expression: binding of c-Myb and CpG methylation of 59
regulatory sequences. Mutation of other putative transcription factor binding sites suggests that additional factors regulate
vav1 expression as well.
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Introduction
The specification and maintenance of tissues is a fundamental
aspect of development, mediated in part by hierarchical networks of
transcription factors and cis-regulatory elements that control gene
expression. Additionally, somatic epigenetic inheritance, particularly
through DNA methylation and chromatin remodeling, plays a
critical role in regulating the development of multicellular eukaryotic
organisms [1].
Hematopoiesis is one of the best-studied examples of develop-
ment and differentiation from stem cell maintenance to lineage
commitment and differentiation [2]. Vav1 expression, which is
strictly confined to the hematopoietic system [3], is upregulated in
the aorta-gonad-mesonephros (AGM) region of the embryo during
the switch from primitive to definitive hematopoiesis [4] and is
subsequently expressed only in cells of the adult hematopoietic
system [3]. The AGM is an important intraembryonic source of
hematopoietic stem cells and the appearance of these stem cells
correlates with the upregulation of vav1 expression. Definitive
hematopoietic stem cells appear to differentiate from the ventral
hemogenic endothelium of the dorsal aorta and enter the
developing circulatory system to seed the fetal liver [5], where
erythrocytic, myeloid, and lymphoid lineages develop. In newborn
and adult mice, vav1 is expressed specifically in hematopoietic cells
from the thymus, lymph node, bone marrow, and spleen [5]. Vav1
was first identified in a screen for oncogenes in which NIH3T3
cells were transfected with DNA from several esophageal
carcinomas [3]. Nucleotide sequence analysis revealed that the
Vav1 oncogene was activated in vitro and the isolated mutant form
was not present in the original tumor sample [3].
Several characteristic structural motifs enable Vav1’s signal
transducer function [6–8]. The best-known function of Vav1 is as
a GDP/GTP exchange factor for Rho/Rac, a function strictly
controlled by tyrosine phosphorylation [6–8]. Rho/Rac activation
leads to cytoskeletal rearrangement during activation of T cells
[6–8]. There is also increasing evidence suggesting that Vav1 has
other effects that are independent of its exchange activities,
including modulating the JNK, ERK, Ras, NF-kB, and NFAT
pathways. These effects are likely mediated by Vav1’s modular
domains via interaction with other proteins, including Shc, NCK,
SLP-76, GRB2, and Crk [6–8].
We initially characterized the vav1 promoter 20 years ago [9].
Analysis of the promoter region determined the transcription start
sites and indicated that the promoter lacks identifiable core
promoter elements such as a TATA box or an initiator. However,
it does contain several consensus binding sites for both ubiquitous
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OCT, and ETS proteins) transcription factors [9]. The murine
promoter was cloned subsequently [10,11]. RNase protection
experiments were performed on mRNA from cell lines represen-
tative of diverse hematopoietic lineages. All these RNA samples
yielded a pattern of fragments corresponding to a cluster of major
and minor start sites 95 to 133 bp upstream of the translation
initiation codon, near the multiple start sites mapped for the
human vav1 mRNA [10,11]. Thus, a single vav1 promoter appears
to be operative throughout the hematopoietic compartment. As
expected, the promoter of vav1 was shown to drive transgene
expression in multipotent hematopoietic stem cells residing in the
bone marrow of adult mice as well as in various hematopoietic
organs [12–14]. For instance, several independent lines of human
NPM-ALK transgenic mice were generated by using the
hematopoietic cell-specific vav1 promoter. This new transgenic
model provided a system for investigating the oncogenic events
mediated by NPM-ALK in situ [14]. Also, lentiviral vectors
expressing the common cytokine receptor gamma chain under the
control of the proximal vav1 gene promoter were shown to be
effective for correction of signaling defects and the X-linked severe
combined immunodeficiency (SCID-X1) disease phenotype in a
murine model [13].
Although vav1 promoter has been used to drive specific
expression in the hematopoietic system, little is known about the
transcription factors that regulate its activity. In a series of studies,
Denkinger et al. demonstrated that PU.1 is essential for transcrip-
tional activity of the vav1 promoter in myeloid cells, but not in other
hematopoietic cells [15]. Moreover, Vav1 and PU.1 are recruitedto
the CD11b promoter in APL-derived promyelocytes, suggesting
that the ATRA-induced increase of Vav1 expression and tyrosine
phosphorylationmay be involved in recruitingPU.1 to its consensus
sequence on the CD11b promoter and, ultimately, in regulating
CD11b expression during the late stages of neutrophil differenti-
ation of APL-derived promyelocytes [16].
Vav1 mutations have not been detected so far in human cancer.
Thus, although truncated versions of Vav1 lacking the amino
terminus transform NIH3T3 fibroblasts [9,17] and synergize with
active Ras in transformation [18,19], their role in human
tumorigenesis is disputed [20]. A number of groups, including
ours, have detected the ectopic expression of Vav1 in neuroblas-
toma [21], pancreatic ductal adenocarcinomas (PDA) [22] and
lung cancer [23]. These findings suggest that ectopic Vav1
expression may be a more general phenomenon affecting
additional tumor types. Determining what drives aberrant Vav1
expression in tissues outside the hematopoietic system is important
for understanding Vav1’s involvement in human cancer.
Our current study reveals the involvement of the hematopoietic
transcription factor c-Myb in the expression of vav1 in lung cancer
cells. We also demonstrate the contribution of CpG dinucleotide
methylation of the vav1 promoter to its expression in hematopoi-
etic and cancer cells.
Materials and Methods
Cell lines
Jurkat (acute T cell leukemia, kindly given to us by Dr. Weiss
[24]), U937 (monocytes, histiocytic lymphoma [25]), H441 (lung
papillary adenocarcinoma, kindly given to us by Drs. Gazdar and
Minna [26]), H460 (large cell lung cancer kindly given to us by
Drs. Gazdar and Minna [26]) and H358 (bronchioalveolar Non-
Small Lung Carcinoma, kindly given to us by Drs. Gazdar and
Minna [26]) cells were grown in RPMI medium. Panc1
(pancreatic duct epithelioid carcinoma, kindly given to us by Dr.
Billadeau [22]) and A549 (lung epithelial carcinoma, kindly given
to us by Drs. Gazdar and Minna [26]) cells were grown in DMEM
medium (Sigma). All media was supplemented with 10% Fetal
Bovine Serum (FBS), Penicillin-Streptomycin and L-Glutamine
(Biological Industries, Israel) and cells were maintained at 37uC
with 5% CO2.
Promoter-reporter constructs and site-directed
mutagenesis
The firefly luciferase vector pGL3-basic and Renilla luciferase
vector pRL-CMV (Promega, USA) were used in this study. The
proximal 59 region of human vav1 gene [2287 to +301 relative to
the transcription start site (TSS)] was cloned with primers lil30 and
lil32 (Table 1) and inserted in-frame into pGL3-basic reporter
vector using SacI and XhoI restriction sites to create construct
Le2. Le2 was then used as the template to generate a series of
point mutations and deletions (Table 1). The PCR reactions were
performed using Pfu-X Polymerase (Jena Bioscience, Germany)
under the following conditions: 94uC, 5 min; 35 cycles of (94uC for
15 seconds, 55–62uC for 30 seconds, 72uC for 1 min for lil30 and
lil31, and for 4 min for the other primer pairs as described in
Table 1). The PCR products were purified from 1% agarose gel
using the Wizard SV Gel and PCR Clean-Up System (Promega,
USA). The lil30-32 fragment was digested with SacI and XhoI
restriction enzymes and ligated into pGL3 vector using Fast-Link
DNA ligation kit (Epicentre, USA). PCR products of site-direction
mutagenesis were self-ligated.
Transient transfections and luciferase reporter assay
Cells were seeded and transfected after 24 h under conditions
shown in Table 2. Cells were harvested 24 or 48 hrs after
transfection. Luciferase reporter assays were performed with Dual-
Luciferase Reporter System (Promega, USA) using Luminometer
Mithras (Berthold Technologies, Germany). For the c-Myb
overexpression experiments, 1 mg of c-Myb expressing plasmid
Table 1. Primers used for preparation of the vav1 promoter
constructs*.
Construct
Primer
name Sequence (59-.39)
Le2 (Sense) lil30 AAGAGCTCGAAGTGGGTGAATTCTGGG
Le2 (Antisense) lil32 AACTCGAGCTGGGACATCTGGGGC
Le7 (Sense) lil40 CAGGCAAAGAAGAGGAAG
Le7 (Antisense) lil41 TTTCTGTCGCCCTGAGAG
Le12 (Sense) lil38 CAGGCAAAGAAGAGGAAG
Le12 (Antisense) lil39 TAACTGGTGCCCTGAGAGG
Le13 (Sense) lil59 GAAAAAGTGGTAGCACTAGCTGTC
Le13 (Antisense) lil60 TGAGAGGGGGTGGAGGA
Le15 (Sense) lil69 GAAAAAGTGGTAGCACTAGCTGTC
Le15 (Antisense) lil70 TTCTTTGCCTGTAACTGTCG
Le17 (Sense) lil57 GTAGCACTAGCTGTCGC
Le17 (Antisense) lil58 CTGTAACTGTCGCCCTGA
Le19 (Sense) lil71 GCAAAGAAGAGGAAGTGGT
Le19 (Antisense) lil72 CTGTAACAATCGCCCTGAG
Le20 (Sense) lil75 GAAAGAGATGTCAGATTCTG
Le20 (Antisense) lil76 CTCGACACGGCCTG
*The underlined sequences correspond to the nucleotide replacement
mutations.
doi:10.1371/journal.pone.0029939.t001
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reporter construct and Renilla into H460 cells. The cells were
harvested 24 hrs after transfection. Methylated Le2 plasmid was
prepared using CpG methyltransferase (M.SssI) (New England
Biolabs, USA).
Bisulfite sequencing
DNA from normal human tissues was obtained from BioChain
(USA). Bisulfite reaction was performed using EZ DNA Methyl-
ation-Direct Kit (Zymo Research, USA). The sequences of interest
were amplified by PCR with primers lil11 (ACACACC-
TAAACCCCATC) and lil53 (GGGTTGGATTAGATA-
GAGGA) using 2 mlo f1 0ml total volume of the bisulfitization
reaction, Tm=55uC, 35 cycles. PCR products were purified and
cloned into the pGEMT plasmid (Promega, USA). Ligated
plasmids were used to transform DH5a competent cells. PCR
was then performed on bacterial colonies with standard primers
for T7 and SP6 promoters. The PCR products of correct length
were sequenced by Macrogen (Korea).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were isolated as described [15]. To obtain
short double stranded DNA probes, single-stranded oligonucleo-
tides (IDT, USA) (Table 3) were annealed and then labeled with
Digoxigenin Oligonucleotide 39-End Labeling Kit (Roche, Swit-
zerland). The long wild type Le2 probe was created by PCR with
Digoxigenin labeled primers lil46 (59-GCTGCAGGTGCTCC-39)
and lil47 (59-CCTGCTCGCCTGTG-39) using the Le2 plasmid
as a DNA template. For probes that containing mutations, same
primers were used and corresponding mutated plasmid was used
as a template. The DNA-protein binding reactions were
performed at room temperature for 15 min in a total volume of
20 ml. The reaction contained 60 fmole labeled DNA probe, 4 mg
nuclear extract, 2 mg poly(dINdC) and binding buffer (1 mM Tris
pH 7.5, 7.5 mM NaCl, 1 mM EDTA, 0.1 mM DTT, 0.7%
glycerol). For competition assays, 1- to 10-fold unlabeled double-
stranded DNA was added in the reaction mix 10 min prior to the
labeled probe addition. Reaction mixtures were then separated on
4% non-denaturing polyacrylamide gel. Electrophoresis was
performed in 0.56TBE buffer at room temperature at 60 volt
for 1 hr. The DNA-protein complexes were transferred to
positively charged nylon membrane (Roche, Switzerland), cross-
linked by UV using UV Stratalinker 2400 (Stratagene, USA).
Digoxigenin-labeled DNA was detected with DIG Gel Shift Kit,
2
nd generation, using CDP-Star substrate (Roche, Switzerland).
Images were exposed to X-ray films for 15–20 min.
Annealing
Lyophilized complementary oligonucleotides were diluted to
100 mM, and then mixed in equimolar concentrations in
annealing buffer (10 mM Tris, pH 7.5–8.0, 50 mM NaCl,
1 mM EDTA) for final concentration of 3 mM each. Annealing
mixture was heated to 100uC for 5 min and slowly cooled to 30uC
during 1 hr.
Table 2. Transfection conditions for different cell lines used in this study.
Cell line Plate Density Total volume (ml) Transfection reagent Le2 (mg) Renilla (ng)
Jurkat 12 well 5610
5/ml 4 Electroporation (BioRad, USA) 2 20
U937 24 well 5610
5/ml 1 Lipofectamine 2000 (Invitrogen,USA) 2 20
H441 6 well 5610
5/well 4 JetPEI (Polyplus, France) 2 20
H460 6 well 2610
5/well 4 JetPEI (Polyplus, France) 2 20
Panc1 6 well 10
5/well 4 JetPEI (Polyplus, France) 2 20
A549 6 well 10
5/well 4 JetPEI (Polyplus, France) 2 20
doi:10.1371/journal.pone.0029939.t002
Table 3. Oligonucleotides used in EMSA, introduced mutations are underlined.
Description Oligonucleotides Sense (59-.39) Antisense (59-.39)
E2F/NF-e/c-Myb and TCF m/PU.1/
ELF1 binding sites (245 to 0)
lil157-158 CCCTCTCAGGGCGACATTACAGG-
CAAAGAAGAGGAAGTGGTAGC
GCTACCACTTCCTCTTCTTTGCCTG-
TAACTGTCGCCCTGAGAGGG
227–28 TT.AA substitution (245 to 0) lil159-160 CCCTCTCAGGGCGACAGAAACAGG-
CAAAGAAGAGGAAGTGGTAGC
GCTACCACTTCCTCTTCTTTGCCTGT-
TTCTGTCGCCCTGAGAGGG
232–33 GA.AC substitution (245 to 0) lil161-162 CCCTCTCAGGGCACCAGTTACAGG-
CAAAGAAGAGGAAGTGGTAGC
GCTACCACTTCCTCTTCTTTGCCT-
GTAACTGGTGCCCTGAGAGGG
E2F/NF-e/c-Myb binding site (239 to 222) lil87-88 CAGGGCGACAGTTACAGG CCTGTAACTGTCGCCCTG
227–28 TT.AA substitution (239 to 222) lil89-90 CAGGGCGACAGAAACAGG CCTGTTTCTGTCGCCCTG
232–33 GA.AC substitution (239 to 222) lil147-148 CAGGGCACCAGTTACAGG CCTGTAACTGGTGCCCTG
Sp1 binding site (2160 to 2141) lil79- 80 GTGTCGAGTGGGCGGAAGAA TTCTTCCGCCCACTCGACAC
CpG 3+4 methylated (2160 to 2141) lil85-86 GTGTmetCGAGTGGG
metCGGAAGAA TTCTT
metCCGCCCACT
metCGACAC
CpG3 methylated (2160 to 2141) lil81-84 GTGT
metCGAGTGGGCGGAAGAA TTCTTCCGCCCACT
metCGACAC
CpG4 methylated (2160 to 2141) lil82-83 GTGTCGAGTGGG
metCGGAAGAA TTCTTC
metCGCCCACTCGACAC
doi:10.1371/journal.pone.0029939.t003
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RNA isolated with TRIzol reagent (Invitrogen, USA). Total
RNA (2 mg) was reverse-transcribed with M-MLV polymerase and
random hexamer primer (Promega, USA) in a total reaction
volume of 20 ml. PCR was performed with GoTaq Green Master
Mix (Promega, USA) and 1 ml of the cDNA; for actin detection
cDNA was diluted tenfold. Primers for the different genes are
listed in Table 4.
Immunoblot Assay
Jurkat, H441 and H460 cell lines were processed for protein
extraction and Western blotting using standard procedures.
Briefly, the cells were washed twice in PBS and lysed in lysis
buffer (50 mM Tris pH 7.6, 150 mM NaCl 5 mM EDTA, 0.5%
NP40) containing protease inhibitors (0.1 mM phenyl-methyl
sulphonyl fluoride; Halt Protease Inhibitor cocktail (Thermo
Scientific), 5 mM EDTA), kept at 4uC for 15 min, centrifuged
for 10 min at 12000 g and supernatants were collected. Twenty
five mg of protein lysates was resolved in 8% SDS-PAGE. Resolved
proteins were transferred on to the nitrocellulose membrane. After
quick washing in TBST (50 mM Tris.HCl, pH 7.4, 150 mM
NaCl, 0.2% Tween), the membranes were blocked in 3% BSA for
1 hr and then incubated with primary antibodies for c-Myb (Santa
Cruz),Vav1 (Upstate Biotechnology Inc, USA), and b-actin (Santa
Cruz) (diluted in 1% BSA in TBST) overnight at 4uC. The
membrane was then washed (3610 min) in TBST at room
temperature and probed with 1:10000 diluted horseradish
peroxidase-conjugated anti-mouse or anti-rabbit secondary anti-
bodies for 1 hr at room temperature and washed 3610 min with
TBST. The signal was detected with an ECL chemiluminescence
kit (Pierce, USA).
Results
The minimal promoter region of human vav1 and its
tissue specific expression
The sequences of the minimal promoter region of human and
murine vav1 have been published (Gene ID: 7409 and Gene ID:
22324, respectively). Analysis of the human vav1 promoter with
TESS (Transcription Element Search System; http://www.cbil.
upenn.edu/cgi-bin/tess/tess) reveals numerous putative binding
sites for transcription factors including ETF, Sp1, E2F, NF-e, c-
Myb, TCFa, PU.1 and ELF-1 (Figure 1, boxed). In addition, the
promoter contains 8 potential CpG methylation sites (Figure 1,
highlighted in red and numbered arbitrarily 1–8).
Tissue-specific expression of genes can be achieved by activity of
tissue-specific transcription factors as well as by regulation of the
affinity between DNA-binding factors and promoter sequences.
To identify regulatory sequences required for the restricted
expression of vav1, we generated a pGL3-vav1 reporter construct
(Le2) containing the minimal regulatory sequences of vav1
proximal promoter region [from nucleotide (nt) 2287 to +301
relative to Transcription Start Site (TSS)] upstream of a luciferase
reporter gene. To validate that the expression of Le2 corresponds
with the endogenous expression of vav1 in cells of different
histological origins, the plasmid was transfected into Jurkat T cells
and U937 monocyte cells in which vav1 is expressed physiolog-
ically, and into H441 lung cancer cells, where it is aberrantly over-
expressed [23]. Le2 was also transfected into vav1-negative cell
lines: lung cancer cells H460 and A549 [23]) and pancreatic
cancer cell line Panc1 [22] (Fig. 2A). Following transfection,
luciferase was expressed at high levels in the Vav1-expressing cells
(Jurkat, U937 and H441), but its expression level was very low in
the vav1-negative cell lines (H460, A549 and Panc1) Luciferase
expression in H441 lung cancer cells was even higher than in
Jurkat T cells (Fig. 2A).
To characterize the promoter regions involved in vav1
expression, we created several point mutations and deletions in
the predicted transcription factor binding sites (indicated in
Figure 2B) and tested the expression of reporter constructs bearing
these mutations in various cell lines (Figure 2C). Our results clearly
show that each nucleotide substitution or deletion in putative
transcription factor binding sequences reduced the activity of the
promoter compared to the wild type construct, Le2 (Fig. 2C). For
some mutants, we also observed significant differences between
their expression in Jurkat, U937 and H441 cells. For instance,
Le12, Le15 and Le17 are better expressed in Jurkat T cells than in
U937 cells, indicating that even among cells of hematopoietic
origin, there are differences in the regulation of vav1 expression.
Le15 and Le17 carry mutations in the PU.1 binding site,
supporting the need for PU.1 binding in U937 cells. This is
consistent with previous reports of differential requirements for
PU.1 for Vav1 expression in different hematopoietic cells [15].
Le7 and Le12, which have base pair substitutions in a putative
E2F/NF-e/c-Myb binding site, exhibit significantly reduced
luciferase expression in hematopoietic cells; however, these
mutations have only a minor effect on luciferase expression in
H441 lung cancer cells. Deletion of the entire E2F/NF-e/c-Myb
site (Le13) abolishes luciferase expression in all cell lines used in
this study. A point mutation in the ETF/Sp1 binding site (Le19)
has a smaller effect on reporter gene expression in the
hematopoietic cell lines than in the lung cancer cell line, but
again, deletion of the entire binding site (Le20) abolishes luciferase
expression in all cell lines examined in this study. Mutagenesis
in the TCFa/PU.1/ELF-1 binding site (Le15 and Le17) abates
luciferase expression in a similar manner in all cell lines. Thus, our
results point to the involvement of several transcription factors in
regulating Vav1 expression in cells of different histological origin.
To determine if these mutations alter binding of nuclear
proteins to the vav1 promoter, we performed an electrophoretic
mobility shift assay (EMSA). Digoxigenin-labeled double-stranded
oligonucleotides encompassing nucleotides 298 to +25 (lil 46-47)
of the vav1 promoter (Fig. 3) were used as probes in the presence
of nuclear extracts from Jurkat and H441 cells. Wild type
oligonucleotide and oligonucleotides with mutations correspond-
ing to the mutations in the reporter constructs (Fig. 2B) were used.
The protein complexes that assemble on the wild type DNA
sequence in the nuclear extract appear as five major bands (labeled
1–5) in both cell lines; however, the intensity of these bands differs
between the two (Fig. 3 bottom). Thus, band 5 exhibits a higher
intensity in nuclear extract from H441 cells than in nuclear extract
from Jurkat T cells (19.2% vs. 4.9%). Binding of the protein
complex represented by band 5 was partially or completely lost in
Table 4. Primers that were used for gene expression analysis.
Gene Primer name Sequence (59-.39)
vav1 lil 7 CACAGGCGAGCAGGG
vav1 lil 8 CACAGAAGGACACCATCC
c-myb lil 67 TCAGGAAACTTCTTCTGCTCACA
c-myb lil 68 AGGTTCCCAGGTACTGCT
actin lil 14 ACCCTACTCACCTATAAAAC
actin lil 15 CGCAGCTCATTGTAGAAG
doi:10.1371/journal.pone.0029939.t004
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band completely disappeared in the GA.AC and deletion (225–
38) mutants in Jurkat T cells, while in H441 it disappeared only in
the 225–38 deletion mutant, thus potentially corresponding to the
loss of promoter activity of the deletion mutation in H441 cells
(Fig. 2C). Additionally, the intensity of band 4 is lower in the
GA.AC and deletion (225–38) mutants in Jurkat T cells, while it
does not change in H441 cells (Fig. 3). These results clearly
indicate the there are differences in protein complexes assembled
on the promoter region in cells from different origins. Our data
indicates that the region of the vav1 promoter between 298 and
+25 is critical for vav1 expression in various cell lines and encodes
putative binding sites for several transcription factors.
c-Myb is involved in regulation of vav1 expression in
hematopoietic and lung cancer cells
While PU.1 exhibits specificity for the myeloid cell lineage, as
reported previously [27–29], most of the other transcription
factors seem to be ubiquitously expressed, albeit at different levels.
One transcription factor that might affect the level of vav1
expression in lung cancer cells is c-Myb. c-Myb is highly expressed
in immature hematopoietic cells and is down-regulated during
differentiation [30,31]. To determine whether the c-Myb binding
site in vav1 promoter participates in generation of protein
complexes, we used a double-stranded oligonucleotide encom-
passing the binding sites for the transcription factors E2F/NF1-e/
c-Myb and TCFa/PU.1/ELF1 (lil 157-158, Table 3). Mutations
introduced in the c-Myb binding site (TT.AA) affected the
affinity of Jurkat T cells protein complex as determined by a
competition assay (Fig. 4A), while the effect of a mutation in the
E2F binding site (GA.AC) had a lesser effect (Fig. 4A). By using a
shorter oligonucleotide that contains only the c-Myb/E2F binding
site (Table 3, lil87-88); we noticed that only one protein complex is
formed with nuclear extracts of Jurkat T cells (Fig. 4B). This
protein complex is totally disrupted when the TT.AA mutation
(c-Myb binding site) is used, while the GA.AC mutation (E2F
binding site) still forms a similar band to the wild-type
oligonucleotide (WT), albeit at a lower level (Fig. 4B). In
agreement with the results of Figure 4A, mutation in the c-Myb
impair the ability of the protein complex to bind DNA and
GA.AC substitution has a lesser but significant effect.
To further determine whether c-myb is involved in Vav1
expression, we analyzed its expression in cells of different
histological origins and found that c-myb mRNA and protein is
present in Jurkat T cells and at lower levels in H441 lung cancer
cells, but is hardly detectable in H460 lung cancer cells that do not
express vav1 (Fig. 5A). To examine whether c-Myb participates in
the regulation of vav1 expression, we co-transfected a c-Myb
expression vector with either an empty vector or with Le2 into
H460 cells (Fig. 5B). Co-trasnfection of c-myb with Le2 significantly
increases the expression of the reporter gene compared to the
expression of Le2 alone (upper panel). We also determine the level
of c-myb mRNA and protein expression in the transfected cells
(lower panel). Down-regulation of c-myb by transfection of siRNA
into H441 lung cancer cells significantly decreased vav1 expression
(Fig. 5C). Collectively, these results suggest that c-Myb plays a role
in the regulation of vav1 expression in epithelial lung cancer cells.
Methylation of individual CpG sites in human vav1
promoter is important for the regulation of its expression
Changes in DNA accessibility for DNA-binding factors also
participate in regulating gene expression. One mechanism that
affects DNA accessibility is methylation of CpG dinucleotides at
specific protein binding sites [32]. It has been demonstrated that
epigenetic modifications, including methylation, play an important
role in aberrant vav1 expression in pancreatic cancer cell lines [22].
However, this study did not decipher the mechanism in-depth. To
begin to assess the role of methylation in regulation of Vav1
expression, we analyzed methylation of the vav1 promoter in
samples from different normal human tissues (Table 5). About
600 bp of vav1 promoter sequences upstream and downstream of
the TSS were analyzed by bisulfite sequencing. Strikingly, in
lymphocytes, we observed no methylation of any of the putative
CpG methylation sites sequenced. In contrast, in DNA from
tissues that do not normally express Vav1, we detected various
degrees of methylation at sites in the vav1 promoter (Table 5). For
instance, the methylation level in the pancreas is 48–100%, in the
lung the level is between 22–50%, whereas in colon the percentage
of methylation is very low (between 4 to 15 percent). These results
imply that methylation plays an important role in the regulation of
vav1 expression.
To further explore the role of DNA methylation in vav1
regulation, we analyzed the effect of methylation of the vav1
promoter on transcription using methylated and unmethylated
forms of the luciferase reporter gene Le2. To estimate the
efficiency of the methyltransferase reaction, we digested the
unmethylated and methylated plasmids with HpaII, a methyl-
sensitive restriction enzyme (described in Materials and Methods).
Figure 1. Nucleotide sequence of the 59 minimal regulatory region of the human vav1 gene. Boxes indicate putative binding sites for
various transcription factors as predicted by bioinformatics. Their location is indicated relative to the transcription start site (+1 position). Putative
sites for CpG methylation are highlighted in red, their arbitrary serial numbers are circled in green.
doi:10.1371/journal.pone.0029939.g001
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unmethylated plasmid (Fig. 6A). The unmethylated form of Le2
transfected into Jurkat, U937 and H441 cells led to expression of
the reporter gene (Fig. 6B), similar to the results presented in
Fig. 2A. In contrast, luciferase activity was more than 90% lower
in Jurkat and H441 cells transfected with the methylated plasmid
and about 50% lower in U937 cells. These results indicate that
methylation of the vav1 promoter is important for its restricted
tissue specific expression.
The CpG content in vav1 regulatory sequences is not high
enough to create CpG islands. We hypothesized that methylation
of individual CpG sites may interfere with transcription by a
Figure 2. The vav15 9 untranscribed sequences contain cell-type specific cis-regulatory elements. (A) Expression of wild-type (wt)
luciferase reporter gene (Le2) in cell lines from various tissue origins. Le2 was transfected into the cell lines as described in Materials and Methods and
luciferase activity was measured 24 hr later. Data show luciferase activity normalized to Renilla transfection efficiency control and calculated relative
to the luciferase activity of an empty vector expression, pGL3. The experiments were repeated five times. (B) Schematic map of the 59 regulatory
region of the human vav1 gene. Three putative transcription factor binding sites are highlighted by boxes. The changes introduced in these regions
are as follows: nucleotide substitutions (red) and deletions (crooked lines). (C) The effect of these mutations/deletions was analyzed in Jurkat T cells,
U937 myeloid cells and H441 lung cancer cells. Following transfection with plasmids containing luciferase under wt (Le2) or mutated vav1 promoter,
the luciferase activity was measured and fold induction of activity was calculated relative to the activity of Le2. Experiments were repeated five times.
Statistics were performed using the unpaired student T test. (**) indicates p,0.05 value and (***) indicates p,0.01.
doi:10.1371/journal.pone.0029939.g002
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transcription factor binding site for ETF/Sp1 contains a putative
CpG methylation site (CpG4) (Fig. 1), which may affect the
interaction between DNA and DNA-binding proteins. To resolve
this issue, we performed EMSA experiments in the presence of
methylated and unmethylated unlabeled competitor (Fig. 7). A
digoxigenin-labeled double-stranded DNA probe encompassing
CpG3 (2156 bp relative to TSS) and CpG4 (2148 bp) were used.
The probe was incubated in the presence of nuclear extract from
Jurkat T cells and one of the following unlabelled competitor
oligonucleotides: unmethylated at CpG3 and CpG4 positions
(C3C4), methylated at CpG3 and CpG4 (
metC3
metC4), methylated
only at CpG3 (
metC3C4) or only at CpG4 (C3
metC4).
metC3
metC4
and C3
metC4 had no effect on binding to the unmethylated probe,
whereas
metC3C4 reduced binding similarly to the non-methylated
competitor C3C4 (Fig. 7). This result demonstrates that methyl-
ation on the CpG4 dinucleotide interferes with protein binding to
the vav1 promoter, but methylation at CpG3 does not play an
important role in this type of regulation.
Discussion
To investigate the mechanisms underlying tissue-specific and
cancer-related transcription of vav1, we used a reporter gene
approach. We found that luciferase under the control of the vav1
promoter is expressed at a higher level in Jurkat T cells than in
U937 monocytic cells (Fig. 2A). In H441 lung cancer cells,
luciferase expression from the same plasmid was even higher than
in Jurkat T cells (Fig. 2A). These results are consistent with the
physiological expression of vav1, which is particularly high in
lymphocytes and megakaryocytes [33]. Similarly, transgenic mice
expressing hCD4 under the vav1 promoter show that the highest
Figure 3. Mutations at various transcription factors binding sites affect protein complexes formation at the vav1 promoter.
Electrophoretic mobility shift assay (EMSA) with Jurkat and H441 nuclear extracts was performed in the presence of lil46-47 digoxigenin-labeled
probe (nucleotides 298 to +28 of vav1 promoter). To produce the mutant oligonucleotides, the corresponding mutated plasmids (shown in Fig. 2B
schematic) were used as template for the PCR. A schematic of vav15 9 regulatory sequences, exon 1 and relative oligonucleotide position is shown at
the bottom. Bound protein complexes are numbered 1 to 5. The arrow shows the position of complex 5, the heaviest complex that is sensitive to the
mutations introduced into the oligonucleotide sequence. The bottom panels of the figure schematically show the relative intensity of bands 1–5 of
the EMSA experiment as determined by densitometry (ImageJ software).
doi:10.1371/journal.pone.0029939.g003
Figure 4. Mutations at the E2F/NF-e/c-Myb binding site affect
binding of protein complexes to the vav1 promoter in vitro. (A)
Electrophoretic mobility shift assay (EMSA) with Jurkat nuclear extracts
was performed in the presence of digoxigenin-labeled probe spanning
nucleotides 245 to 0 of vav1 promoter and containing E2F/NF-e/c-Myb
and TCFa/PU.1/ELF1 binding sites (lil157-158; Table 3). The competition
assay was performed with the labeled oligonucleotide and unlabeled
competitor oligonucleotides with point mutations as indicated in
Table 3 in molar ratio of 1:1 and 1:5. The arrow shows the position of
the complex that demonstrates sensitivity to the introduced mutations.
(B) EMSA performed with labeled oligonucleotide containing only E2F/
NF-e/c-Myb binding site (lil 87-88; Table 3).
doi:10.1371/journal.pone.0029939.g004
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and megakaryocytes, while monocytes and neutrophils have an
intermediate level of vav1 expression and erythroid cells have the
lowest level [11]. These data validate our reporter approach to
deciphering the regulation of vav1 expression.
Sequence analysis identified several consensus transcription
factor sites in the vav1 promoter, including sites for Sp1, P300 and
YY1, which are expressed ubiquitously [34], and for the tissue-
specific factors c-Myb and PU.1 [27,35,36] (Fig. 1). In our
analysis, mutations at the PU.1 binding site caused dramatic
decreases in reporter gene expression in U937 cells (constructs
Le15 and Le17, Fig. 2C), consistent with the previous report that
PU.1 is critical for vav1 expression in U937 cells [15]. Mutations at
this site also dramatically decreased luciferase expression in Jurkat
T and H441 cell lines. PU.1 expression is restricted to the myeloid
cell lineage and is not expressed in Jurkat T or H441 cells, so it is
unclear which transcription factor binds to this sequence and
enables vav1 transcription in these cell types. PU.1 belongs to the
ETS family of transcription factors, which have highly similar
DNA-binding domains yet have diverse functions and activities
physiologically and in oncogenesis [37]. Sokalski et al. demon-
strated that the function of PU.1 in B cell differentiation is
complemented by the related ETS transcription factor Spi-B,
which binds to the same DNA consensus sequence [38,39]. It is
reasonable to suggest that other members of the ETS family bind
Figure 5. C-Myb is involved in regulation of vav1 expression in lung cancer cells. (A) Endogenous expression of c-myb mRNA in Jurkat T
cells, H441 (vav1-positive) and H460 (vav1-negative) lung cancer cell lines was detected by RT-PCR and western blotting. (B) Empty vector pGL3 or
the Le2 wt reporter construct was transfected either alone or with a c-Myb-expressing plasmid into H460 lung cancer cells (as in Materials and
Methods). Luciferase activity was measured 24 hr after transfection (top panel). Luciferase activity is expressed as fold induction relative to basic pGL3
expression. Values are the mean of five independent experiments; significance was determined using the unpaired student T test. (***) indicates
p,0.01. The bottom panel shows the level of c-myb and actin mRNA and protein expression in the transfected cells as determined by RT-PCR and
Western blotting respectively. (C) H441 lung cancer cells were transfected with either scrambled DNA (-) or with siRNA against c-Myb. Seventy-two
hours later, the mRNA levels of c-myb, vav1 and actin were detected by RT-PCR.
doi:10.1371/journal.pone.0029939.g005
Table 5. Methylation status of CpG dinucleotides in vav1
promoter in tissues of different histological origin*.
Position Colon Pancreas Stomach Lymph Liver Muscle Lung Brain
2247 15 83 41 0 46 33 40 63
2244 7 96 42 0 31 20 40 63
2156 12 74 19 0 31 13 50 75
2148 8 100 59 0 38 33 50 94
2114 4 83 30 0 15 13 50 57
271 4 48 24 0 18 21 22 54
234 4 57 21 0 18 7 30 46
+10 8 77 24 0 27 7 33 71
+21 4 82 13 0 0 0 44 71
+34 4 82 39 0 27 14 38 86
+38 15 82 27 0 45 21 38 93
N 27 24 34 9 13 15 10 16
*Percent of methylation on each CpG site was evaluated by bisulfite
sequencing. Position refers to that of the CpG dinucleotide relatively to
transcription start site (Fig. 1), and N refers to number of sequenced clones.
doi:10.1371/journal.pone.0029939.t005
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T cells and H441 lung cancer cells.
While mutations at the PU.1 binding site had a severe effect on
transcription from the vav1 promoter in all cell lines tested, the cells
responded differentially to mutagenesis at the E2F/NF1-e/c-Myb
or ETF/Sp1 binding sites (Fig. 2B, C). While mutation in the
E2F/NF1-e/c-Myb binding site (Le7 and 12) led to a marked
reduction in the expression of the luciferase reporter in
hematopoietic cell lines, their effect on luciferase expression in
lung cancer cells was minor. In contrast, a point mutation in the
ETF/Sp1 binding site (Le19) affected expression in hematopoietic
cells to a lesser extent than in H441 lung cancer cells. These results
imply that some of the regulatory mechanisms important for vav1
transcription are distinct between different hematopoietic cell
lineages, as well as between hematopoietic cells and lung cancer
cells. Other tissue-specific regulatory mechanisms may affect sites
that are not included in the vav1 promoter sequences in the
reporter construct we used here.
We have identified five protein complexes that bind to the core
promoter region of the vav1 gene in cells of different histological
origins, revealing the complex organization of the regulatory
network of this gene (Fig. 3). Only the heaviest protein complexes
are affected by the mutations that we introduced into the promoter
region (Fig. 2B, Fig. 3). These results raise the possibility that
complexes 1, 2 and 3 are non-specific or that they bind to parts of
the oligonucleotide that are not affected by our mutations and do
not interact with the complexes represented by bands 4 and 5.
Despite the fact that the nucleotides that have been changed in the
oligonucleotides Le7, 12, 13, 15 and 17 define two different
putative transcription factor binding sites, all of these mutations
lead to disappearance of the protein complex represented by band
5 in the EMSA experiments (Fig. 3). This finding may indicate that
the factors that bind to these sites physically interact with each
other to create a high order protein complex that regulates vav1
expression. In Jurkat T cells, deletion of the E2F/NF1-e/c-Myb
binding site also weakened binding of complex 4, whereas deletion
of the TCFa/PU.1/ELF1 site did not (Fig. 3, left, oligonucleotides
Le13 and 17). It may indicate that the complex represented by
band 5 includes the one represented by band 4. It is conceivable
that the protein complexes that associate with the mutated
sequences are slightly different in lung cancer cells and Jurkat T
cells. This could be because different proteins make up the binding
complexes in these cell types or because factors in the complexes
are differentially modified in these cell types in a way that regulates
binding to DNA or to other proteins in the complex.
Our experiments indicate that c-myb could be one of the
transcription factors that contribute to the expression of Vav1
(Figs. 2, 3, 4, 5). First, a mutation in c-Myb binding site impedes
expression driven by vav1 promoter in Jurkat T cells, U937 and
H441 cells (Fig. 2). Second, a mutation introduced in c-Myb
binding site affects protein complex formation (Fig. 4). Third, we
found differential expression of c-myb RNA in cell lines of different
Figure 6. Methylation of CpG sites in the vav1 promoter impairs expression of the reporter gene in various cell lines. (A) Le2 plasmid,
either un-treated or methylated by CpG methyltransferase (M.SssI), was incubated with HpaII and analyzed on a gel. The plasmid treated with M.SssI
was not digested by HpaII, indicating that methylation was successful. (B) Unmethylated or methylated Le2 was transfected into Jurkat T cells, U937
myeloid cells and H441 lung cancer cells. The luciferase activity of these plasmids was measured 24 hr after transfection. Fold induction of luciferase
activity was calculated relative to the activity in cells transfected with unmethylated Le2. Each point is the mean of three experiments. (***) indicates
p,0.01, unpaired student T test.
doi:10.1371/journal.pone.0029939.g006
Figure 7. Methylation on CpG dinucleotides at putative
transcription factor binding sites changes the affinity of
protein complexes for the vav1 regulatory region. (A) EMSA
was performed with Jurkat T cell nuclear extracts and lil3-4 labeled
oligonucleotide. The probe was created by annealing complementary
oligonucleotides lil79 and lil80 (Table 3).-39). The following unlabeled
competitors were added: unmethylated lil79-80 oligonucleotide (C3C4);
oligo methylated on both CpG methylation sites (
metC3
metC4); oligo
methylated only on CpG3 (
metC3C4), or only on CpG4 (C3
metC4).
Competitor oligonucleotide was added in an amount equal to the
labeled oligo (1:1) or in 5 molar excess (1:5).
doi:10.1371/journal.pone.0029939.g007
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cells, somewhat lower levels in H441 lung cancer cells, and not at
all in the H460 lung cancer cell line (Fig. 5A), suggesting that
expression of c-Myb and Vav1 may be correlated in these cells. c-
Myb is essential for hematopoiesis [30,31,40]. In addition, it has
been implicated in progenitor cell maintenance and is required for
proper cellular differentiation in the hematopoietic system,
neuronal cells, skin cells, and colonic crypts [40–43]. c-Myb is
highly expressed in immature hematopoietic cells and its
expression is down-regulated upon differentiation. High c-myb
expression has been associated with oncogenic activity and poor
prognosis in several human cancers, including T-cell leukemia,
acute myelogenous leukemia, colorectal tumors, breast cancer,
and most recently, adenoid cystic carcinomas [35,44,45]. Our
results clearly show an association between the presence of c-Myb
and vav1 expression since over-expression of c-Myb in Vav1-
negative H460 lung cancer cells along with the vav1 reporter gene
induced expression of luciferase (Fig. 5B), while depletion of c-myb
expression in Vav1-positive H441 lung cancer cells led to a
marked reduction in vav1 mRNA expression (Fig. 5C). c-Myb
expression is associated with the control of other genes known to
be linked to cancer. For example, osteopontin (OPN) is a secreted
extracellular matrix protein that has been linked to tumor
progression and metastasis in a variety of cancers. Increased
OPN expression is associated with the clinical stage, portending a
poor prognosis. Inhibition of c-myb by siRNA decreased the
transcriptional activity of the OPN promoter, reduced the
expression of OPN, and compromised the migration and invasion
capacity of Hepatocellular carcinoma (HCC) cells [46]. Vav1 was
also shown to be associated with the expression of OPN [36,46].
Like OPN in HCC, over-expression of Vav1 protein in PDAs [22]
and lung cancers [47] is associated with poor prognosis. In
addition, it is associated with increased migration of the cancer
cells. Collectively, these results raise the possibility that c-Myb
regulates the expression of Vav1 in cancer, thus playing a central
regulator of cells invasive properties in some cancer types.
Ubiquitously active promoters tend to have high CG content
and are regulated by few transcription factors, while tissue-specific
promoters tend to have low CG content and are regulated by
many different proteins [48]. The CpG island is defined as a
sequence of at least 200 to 500 base pairs with CpG content above
55% in which observed to expected ratio is above 0.65. This ratio
is calculated using the formula: (number of CpGs6number of bp)/
(number of Cs6number of Gs) (http://www.uscnorris.com/
cpgislands/cpg.cgi). The CpG content in the vav15 9 regulatory
sequences presented in Figure 1 is relatively high, about 60%, but
the observed to expected CpG ratio is rather low, only 0.32.
Tissue-specific hypomethylation is well correlated with gene
expression profiles that underlie tissue phenotypes. Around these
cell-type specific hypomethylated regions, binding motifs of
particular transcription factors are remarkably enriched. A
combination of tissue-specific promoter hypomethylation and
selective binding of transcription factors is involved in targeting
specific genes during terminal differentiation [49]. Our results
indicate that the promoter of vav1 is totally unmethylated in
lymphocytes where vav1 is normally expressed, whereasother tissues
reveal various levels of methylation (Table 5). This finding, along
withthe highdensityofputative transcriptionfactors bindingsitesin
the vav1 promoter region, suggests that this promoter has
characteristics consistent with other tissue-specific genes.
Our reporter gene studies show that methylation of the vav1
promoter affects transcriptional activity (Fig. 6). Notably, transfection
ofa methylated vav1 promoter- luciferase reporter plasmid into Jurkat
T cells led to a decrease of more than 90% compared to activity in
cells transfected with unmethylated plasmid. In U937 cells, the
methylated plasmid produced about 50% less luciferase activity than
the unmethylated plasmid. This result emphasizes the role of
epigenetic regulation of the vav1 gene and suggests that regulation
of gene expression in theseclosely-related cell lineages - lymphoid and
myeloid - may differ at a number of levels including tissue-specific
transcription factors such as PU.1 [50] and sensitivity to DNA
methylation. This research indicated that the predominant mecha-
nism of vav1 expression regulation is the presence of activating
transcription factors rather than gene repressing mechanisms.
Epigenetic changes are common in most, if not all, human
malignancies. They seem to occur early in cancer development;
consistent with the notion that epigenetic deregulation precedes
and promotes malignant processes. In tumor cells, deregulation of
DNA methylation is found in two forms: the overall loss of 5-
methyl-cytosine (global hypomethylation) and gene promoter-
associated (CpG island-specific) hypermethylation [51]. Notably,
most research on the role of DNA methylation in cancer has
focused on promoters with CpG islands as a regulatory unit.
Fernandez-Zapico et al. showed that no methylation of the vav1
gene was detected in the cell lines that express Vav1 or in DNA
from primary human pancreatic tumors but vav1 promoter
methylation was detected in Panc1 cells that do not express vav1
endogenously. Panc1 cells do express Vav1 following transfection,
indicating that the vav1 gene is not appropriately methylated in
Vav1-expressing cell lines and pancreatic tumor specimens. This
study also showed that treatment of pancreatic cells that do not
express Vav1 with DNA demethylation agents lead to Vav1
expression, suggesting that ectopic expression of Vav1 in primary
pancreatic cancer is the result of an epigenetic modification of the
vav1 gene regulatory sequences. This study proposes that
methylation in the vav1 promoter is the main mechanism of gene
silencing in the pancreatic cells [22]. These findings are in
accordance with our results showing little or no expression from
the methylated vav1 promoter- luciferase reporter construct in
Vav1-expressing Jurkat T cells and H441 lung cancer cells (Fig. 6).
To evaluate which of several CpG sites affects vav1 transcription,
we performed an EMSA experiment with an oligonucleotide that
spans the CpG3 and CpG4 sites. Our results (Fig. 7) show that
methylation at the CpG4 but not at CpG3 is critical for interaction
between proteins and DNA. CpG4 is located within a putative
binding site for the transcription factors ETF and Sp1, but there are
no consensus sequences predicted in the CpG3 location. Katryniok
etal. reportedthatrecruitmentofSp1 toits binding site inthe human
5-lipoxygenase gene promoter is prevented by methylation [32].
However,inanearlierwork,Iguchi-Arigaand Schaffnerdidnot find
aneffectof CpG methylation on Sp1 binding inthe cAMPpromoter
[52]. Sensitivity of a DNA-binding protein to DNA methylation can
be changed by covalent modifications of the protein or by cofactors
that compose the transcriptional complex. Based on these data, Sp1
is a good candidate for regulating vav1 transcription.
Collectively, our experiments show that both tissue-specific
positive transcription factors and epigenetic mechanisms play
important roles in the regulation of vav1 expression.
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